Financial Performance - For the year ended December 31, 2023, the group recorded a net loss of HKD 106.1 million, compared to a net loss of HKD 120.2 million in the previous year, indicating an improvement in financial performance [14]. - The total loss before tax for the group was HKD 119.2 million, with a breakdown of losses from Mainland China at HKD 88.2 million, Hong Kong at HKD 3.0 million, and others at HKD 27.9 million [28]. - The basic loss per share attributable to ordinary shareholders for the year ended December 31, 2023, was HKD (26.85), compared to HKD (30.47) for the previous year [30]. - The adjusted net loss for the group was HKD 106,081,000, with a pre-tax loss of HKD 102,312,000 [188]. - The company reported a net loss of HKD 120,214,000 for the year, compared to a loss of HKD 119,182,000 before tax [199]. Revenue and Sales - Total revenue for 2023 is HKD 406,859 thousand, a decrease of 9.2% from HKD 448,069 thousand in 2022 [51]. - Revenue from sales of concentrated Chinese medicine formula granules is HKD 298,634 thousand in 2023, down from HKD 343,715 thousand in 2022 [51]. - The total sales revenue of Chinese medicine health products in the US, Japan, Hong Kong, and mainland China was HKD 82.0 million, an increase of HKD 3.1 million or 4.0% from last year's HKD 78.9 million [93]. - Revenue from product sales in Hong Kong amounted to HKD 290,989,000, while revenue from mainland China was HKD 62,832,000 [196]. - The concentrated Chinese medicine health products segment in the US recorded sales of HKD 30.1 million, accounting for 36.7% of total sales, representing an increase of HKD 3.3 million or 12.2% from last year [99]. Expenses and Costs - The cost of goods sold for 2023 is HKD 185,881 thousand, an increase from HKD 181,518 thousand in 2022 [55]. - Employee benefits expenses increased significantly to HKD 130,766 thousand in 2023 from HKD 91,351 thousand in 2022 [55]. - Selling and distribution expenses decreased by 41.8% to HKD 91.7 million from HKD 157.4 million, with the percentage of revenue dropping from 35.1% to 22.5% [110]. - Administrative expenses increased by 8.6% to HKD 171.5 million from HKD 157.9 million, driven by higher employee costs and new office leasing in Shenzhen [112]. - Financing costs increased by 13.2% to HKD 27.4 million from HKD 24.2 million, consistent with the increase in average bank borrowings [116]. Assets and Liabilities - As of December 31, 2023, the group's current liabilities net amount was HKD 221.5 million, an increase of 23.5% from HKD 179.4 million in 2022 [15]. - Cash and cash equivalents decreased by 73.5%, from HKD 75.8 million in 2022 to HKD 20.1 million in 2023 [15]. - The group had undrawn bank financing of HKD 105.5 million, which increased by 24.3% from HKD 84.8 million in 2022 [15]. - The company reported a total of HKD 304,023,000 in current borrowings due within one year or on demand, compared to HKD 410,140,000 in the previous year, indicating a reduction of about 26% [74]. - The total value of trade receivables pledged as collateral for bank loans was HKD 55,620,000, down from HKD 58,255,000 in the previous year [67]. Cash Flow - The net cash flow from operating activities for the year ended December 31, 2023, was HKD 79.6 million, a decrease of HKD 8.9 million compared to the previous year [123]. - The net cash used in financing activities increased to HKD 122.4 million, up HKD 86.8 million from the previous year, primarily due to a net decrease in bank loans and other borrowings [125]. - The net cash used in investment activities for the year ended December 31, 2023, was HKD 18.2 million, a decrease from HKD 31.2 million in the previous year, primarily due to a reduction in pledged time deposits and the purchase of property, plant, and equipment [16]. Corporate Governance - The company has adopted the corporate governance code as per the Stock Exchange Listing Rules, ensuring compliance with all applicable provisions [160]. - The audit committee consists of three independent non-executive directors, ensuring proper oversight [163]. - The company believes that the current structure facilitates robust and consistent leadership for effective decision-making [160]. - The independent auditor agreed that the preliminary performance announcement figures for the year ending December 31, 2023, are consistent with the consolidated financial statements [169]. Future Plans and Strategies - The company plans to continue diversifying its business and expanding into the Greater Bay Area, focusing on modernizing and smartening traditional Chinese medicine clinics over the next two years [88]. - The company plans to utilize approximately HKD 282.0 million of the net proceeds from its IPO for various purposes, including expanding production facilities and establishing new TCM clinics in Hong Kong and China [141]. - The company anticipates that the demand for health products will rise due to increased consumer health awareness, providing more opportunities for its Chinese medicine health products segment [100]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth [196].

Revenue Performance - The sales revenue of concentrated Chinese medicine granules in Hong Kong reached HKD 106.8 million during the mid-term period of 2023, an increase of HKD 23.1 million or 27.6% compared to HKD 83.7 million in the same period last year[1]. - The revenue generated from the company's clinics increased to HKD 25.6 million, up HKD 3.5 million or 15.8% from HKD 22.1 million year-on-year, attributed to enhanced clinic network services and increased demand due to COVID-19 and flu transmission[3]. - The total sales revenue of Chinese medicine health products in the US, Japan, and Hong Kong was HKD 37.5 million, a decrease of HKD 0.8 million or 2.2% from HKD 38.3 million in the same period last year[10]. - For the six months ended June 30, 2023, the company recorded revenue of HKD 195.1 million, a decrease of HKD 35.7 million or 15.5% compared to HKD 230.8 million in the same period last year[120]. - Revenue from Chinese concentrated traditional Chinese medicine (TCM) decreased significantly by HKD 55.1 million or 71.2%, contributing to the overall revenue decline[120]. - Revenue from Hong Kong and overseas concentrated TCM increased by HKD 23.1 million or 27.6%, accounting for 54.7% of total revenue[120]. Profitability and Expenses - The gross profit margin for the mid-term period of 2023 was 57.4%, down 7.6 percentage points from 65.0% in the same period last year, primarily due to higher production costs under new standards[15]. - Other income and gains decreased to HKD 6.1 million, down HKD 1.8 million or 23.3% from HKD 7.9 million in the same period last year, mainly due to a reduction in government subsidies[16]. - Sales and distribution expenses were HKD 50.2 million, a decrease of HKD 32.2 million or 39.1% from HKD 82.4 million year-on-year, resulting in a reduction in the percentage of sales and distribution expenses to revenue from 35.7% to 25.7%[21]. - Administrative expenses totaled HKD 80.6 million, a slight increase of HKD 0.6 million or 0.8% from HKD 80.0 million year-on-year[23]. - The group recorded a net loss of HKD 37.7 million for the first half of 2023, an improvement from a net loss of HKD 39.9 million in the same period last year, mainly due to increased sales in Hong Kong and overseas segments[33]. - The net loss for the same period was HKD 37.7 million, an improvement of HKD 2.2 million or 5.6% from a net loss of HKD 39.9 million in the previous year[121]. Financial Position - As of June 30, 2023, the group's current liabilities net amounted to HKD 205.6 million, an increase from HKD 179.4 million as of December 31, 2022, with cash and cash equivalents at HKD 48.1 million[32]. - The debt-to-equity ratio as of June 30, 2023, was 1.9, slightly up from 1.8 as of December 31, 2022, reflecting a stable financial position despite a decrease in interest-bearing bank borrowings[35]. - The total assets less current liabilities amounted to HKD 296,059 million, down from HKD 351,091 million, indicating a decrease of approximately 15.7%[174]. - The company’s non-current assets totaled HKD 501,676 million as of June 30, 2023, compared to HKD 530,501 million as of December 31, 2022, representing a decrease of about 5.4%[182]. - The company’s cash and cash equivalents were HKD 48,073 million as of June 30, 2023, down from HKD 75,831 million as of December 31, 2022, indicating a decline of approximately 36.7%[182]. Capital Expenditures and Investments - Capital expenditures totaled HKD 10.2 million in the first half of 2023, significantly lower than HKD 43.9 million in the same period last year, primarily for purchasing new production equipment for the Nanning factory[34]. - The company incurred capital expenditures of HKD 10,150,000 during the reporting period[195]. Shareholder Information - As of June 30, 2023, the total issued shares of the company were 395,897,275[57]. - The major shareholders include Mr. Chen Yu-ling, holding 45.18% of the shares, and Ms. Wen Yi-hui, holding 19.54%[51]. - The total number of shares that may be issued upon the exercise of options under the share option scheme is 16,329,091 shares as of June 30, 2023[63]. - The total number of shares available for issuance under the share option scheme represents approximately 6.07% of the company's issued share capital as of June 30, 2023[64]. - The company reported a net share reward expense of HKD 39,000 for the six months ended June 30, 2023, consistent with the previous year[83]. Strategic Initiatives - The company plans to expand its clinic network into the Greater Bay Area to explore market opportunities, leveraging its brand recognition in Hong Kong[3]. - The company is focusing on developing innovative new health products and enhancing online marketing strategies to reach broader markets in China and overseas[10]. - The company plans to enhance its R&D capabilities for high-quality concentrated TCM products and develop innovative health products featuring natural ingredients[112]. - The company aims to expand its market presence in the Greater Bay Area by establishing a network of small and medium-sized clinics and leveraging successful store experiences[113]. - The company is focusing on online marketing to promote competitive products and enhance customer loyalty in preparation for retail market recovery[112]. Compliance and Governance - The company has adopted the corporate governance code as per the listing rules, ensuring compliance with all applicable provisions during the six-month period ending June 30, 2023[94].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，且明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 PURAPHARM CORPORATION LIMITED 培 力 農 本 方 有 限 公 司 （於開曼群島註冊成立的有限公司） 1498 （股份代號： ） 截至二零二三年六月三十日止六個月之 中期業績公告 財務摘要 截至六月三十日止六個月 二零二三年 二零二二年 收入 佔總額 收入 佔總額 變動 % 千港元 百分比 千港元 百分比 千港元 22,311 11.5% 77,429 33.6% (55,118) (71.2%) 中國濃縮中藥配方顆粒 106,755 54.7% 83,668 36.3% 23,087 27.6% 香港及海外濃縮中藥配方顆粒 37,465 19.2% 38,309 16.6% (844) (2.2%) 中藥保健品 ...

Financial Performance - The company reported a significant increase in revenue for 2022, reaching HKD 1.2 billion, representing a growth of 15% compared to the previous year[22]. - The total revenue for the year ended December 31, 2022, was HKD 448.1 million, a decrease of HKD 211.5 million or 32.1% compared to HKD 659.6 million in the previous year[120]. - The net loss for the company was HKD 120.2 million, a slight decrease of HKD 1.7 million or 1.4% from the previous year's loss of HKD 121.9 million, primarily due to a decline in sales of concentrated Chinese medicine granules[70]. - Adjusted operating loss for the year was HKD 63.7 million, a decrease of HKD 82.6 million compared to an adjusted operating profit of HKD 18.9 million in the previous year[120]. - The gross profit for the year was HKD 262.7 million, a decrease of HKD 160.6 million or 37.9% from HKD 423.4 million in the previous year[118]. Customer and Market Growth - User data showed a 20% increase in active customers, totaling 500,000 by the end of 2022[22]. - User data showed an increase in active users by 25%, reaching a total of 500,000 users by the end of 2022[26]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 12%[22]. - The company provided a positive outlook for 2023, projecting a revenue growth of 20% driven by new product launches and market expansion strategies[26]. - The company plans to expand its operations into Southeast Asia, aiming for a revenue contribution of 15% from this region by 2025[26]. Product Development and Innovation - New product launches included three herbal supplements, which are expected to contribute an additional HKD 100 million in revenue[22]. - Investment in new product development increased by 30%, with a budget allocation of HKD 300 million for research and development initiatives[26]. - The company is investing HKD 50 million in R&D for new technologies aimed at enhancing product efficacy[22]. - A new technology platform is set to launch in Q3 2023, expected to improve user engagement by 40%[26]. - The company launched a new immune-boosting product, Yikangshi+™, which is rich in Vitamin C and produced in Japan[58]. Strategic Initiatives - Market expansion plans include entering two new Southeast Asian countries by Q3 2023[22]. - The company is considering strategic acquisitions to enhance its market position, with a budget of HKD 200 million allocated for potential targets[22]. - The company is exploring potential acquisitions to enhance its market presence, targeting a 10% increase in market share by 2024[26]. - The company has established strategic partnerships with three key players in the industry to enhance its product offerings and distribution channels[26]. - The company plans to enhance the research and promotion of high-quality concentrated TCM granule products and develop innovative health products featuring natural ingredients, aiming to increase market share[73]. Sustainability and ESG Efforts - The management emphasized a focus on sustainability initiatives, aiming to reduce carbon emissions by 25% by 2025[22]. - The company received the ESG Care Prize from Society Next Foundation for its contributions to sustainable development and environmental protection[54]. - The board has established an Environmental, Social, and Governance (ESG) committee to oversee ESG management and reporting[182]. - The group has intensified efforts on ESG issues due to the impacts of COVID-19, recognizing climate-related risks as a major threat to operations[179]. - The company aims to enhance its climate change adaptability through extreme weather event forecasting and response capability building[192]. Operational Efficiency - The gross profit margin improved to 45%, up from 42% in the previous year, indicating better cost management[22]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies[26]. - Selling and distribution expenses decreased to HKD 157.4 million, down HKD 62.6 million or 28.5% from HKD 220.0 million last year[140]. - Administrative expenses totaled HKD 157.9 million, a decrease of HKD 10.5 million or 6.3% from HKD 168.5 million last year[143]. - The company has committed to responsible and ethical procurement practices, considering the environmental and social impacts of its products and services[196]. Supply Chain and Production - The company has established its own herbal medicine plantation in Guizhou Province, capable of harvesting over 50 types of medicinal materials to ensure a stable supply of high-quality herbs[193]. - The number of suppliers in China increased from 144 in 2021 to 402 in 2022, indicating significant growth in the supplier network[198]. - The company emphasizes strict quality control measures, adhering to production quality management standards set by NMPA, TGA, and USP[200]. - The company operates a state-of-the-art traditional Chinese medicine production facility in Nanning, Guangxi, covering approximately 17,241 square meters with a total building area of about 7,760 square meters, certified by GMP, TGA, PIC/S, and USP standards[89]. - A new smart factory is under construction in Nanning, covering about 49,185 square meters with a total building area of approximately 65,967.66 square meters, aimed at transitioning from traditional automation to fully interconnected systems[90].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，且明確表示概不就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致的任何損失承擔任何責任。 PURAPHARM CORPORATION LIMITED 培 力 農 本 方 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1498） 截至二零二二年十二月三十一日止年度之 全年業績公告 財務摘要 截至十二月三十一日止年度 二零二二年 佔總額 二零二一年 佔總額 變動 千港元 百分比 千港元 百分比 千港元 % 收入 — 中國濃縮中藥配方顆粒 117,751 26.3% 352,996 53.5% (235,245) -66.6% — 香港濃縮中藥配方顆粒 192,094 42.9% 162,740 24.7% 29,354 18.0% — 中藥保健品 78,858 17.6% 78,098 11.8% 760 1.0% — 農本方®中醫診所 46,112 10.3% 50,027 7.6% (3,915) -7.8% — 種植 13,254 2.9% 15,731 2.4% (2,47 ...

Financial Performance - For the six months ended June 30, 2022, the group's revenue was HKD 230.8 million, a decrease of HKD 72.0 million or 23.8% compared to the same period last year[8]. - The group recorded a net loss of HKD 39.9 million for the six-month period, compared to a net profit of HKD 12.0 million in the same period last year, primarily due to a decline in sales of concentrated Chinese medicine granules[8]. - The company's revenue for the six months ended June 30, 2022, was HKD 230.8 million, a decrease of HKD 72.0 million or 23.8% compared to HKD 302.8 million in the same period last year[16]. - The net loss for the period was HKD 39.9 million, compared to a profit of HKD 11.9 million in the same period last year, primarily due to a slowdown in the concentrated Chinese medicine granules business[17]. - Total revenue for the first half of 2022 was HKD 230.76 million, a decline of 23.8% from HKD 302.76 million in the same period last year[33]. - Gross profit for the first half of 2022 was HKD 150.1 million, down 23.6% from HKD 196.4 million in the previous year, with a stable gross margin of 65.0%[33]. - The company reported a net loss attributable to equity holders for the period was HKD 39,903,000, a significant decline from a profit of HKD 11,974,000 in the same period last year[99]. - Basic and diluted loss per share for the period was HKD (10.12), compared to earnings of HKD 3.04 per share in the previous year[99]. Revenue Breakdown - Revenue from concentrated Chinese medicine granules in China was HKD 77.4 million, a decline of HKD 79.5 million or 50.6% from HKD 156.9 million in the previous year[19]. - Revenue from concentrated Chinese medicine granules in Hong Kong and overseas increased to HKD 83.7 million, up HKD 11.0 million or 15.1% from HKD 72.7 million in the previous year[20]. - Revenue from the company's clinics decreased to HKD 22.1 million, down HKD 1.8 million or 7.7% from HKD 23.9 million in the previous year, attributed to a reduction in the number of operating clinics[22]. - Sales revenue for traditional Chinese medicine health products in the US, Japan, and Hong Kong totaled HKD 38.3 million, a decrease of HKD 1.1 million or 2.7% compared to HKD 39.4 million in the same period last year[28]. - Revenue from the sale of concentrated Chinese medicine granules was HKD 177,598, down 28.2% from HKD 247,311 in the previous year[144]. Expenses and Costs - Selling and distribution expenses were HKD 82.4 million, a decrease of HKD 10.1 million or 10.9% from HKD 92.4 million in the previous year, with the percentage of revenue increasing from 30.5% to 35.7%[36]. - Administrative expenses totaled HKD 80.01 million, a slight decrease of HKD 2.28 million or 2.8% from HKD 82.29 million in the previous year[37]. - Other expenses increased significantly to HKD 18.4 million, an increase of HKD 16.1 million or 687.2% compared to HKD 2.3 million in the previous year, primarily due to a HKD 14.1 million loss in the fair value of biological assets[40]. - Financing costs rose to HKD 14.0 million, an increase of HKD 0.5 million or 3.7% from HKD 13.5 million in the previous year due to higher market interest rates[41]. Market and Regulatory Environment - The pandemic has significantly impacted the research and development progress and new product iterations, leading to delays in planned projects[7]. - The national regulatory environment for traditional Chinese medicine granules is tightening, contributing to a negative growth trend in the domestic market for these products[8]. - Future policies in the pharmaceutical industry are expected to compress profit margins, requiring companies to adapt their marketing strategies and invest in research and development[11]. - The implementation of national standards for traditional Chinese medicine granules marks the beginning of a new development phase for the industry, with opportunities for local enterprises[12]. Strategic Initiatives - The group aims to continue developing innovative health products featuring natural ingredients and maintain high-quality concentrated Chinese medicine granules[12]. - The company is preparing for market recovery by focusing on online marketing strategies to reach a broader customer base[12]. - The company plans to expand its clinic network in the Greater Bay Area and has allocated a budget to optimize its cloud consultation management system[16]. - The company aims to enhance its online retail business through extensive social marketing plans to cater to the younger generation and drive revenue growth[16]. - The group is committed to modernizing traditional Chinese medicine and discovering effective new extracts from plants[12]. Cash Flow and Financing - The net cash flow from operating activities for the six months ended June 30, 2022, was HKD 75,053,000, significantly up from HKD 24,800,000 in the previous year, indicating a growth of about 202.5%[121]. - The group had undrawn bank financing of HKD 151.8 million as of June 30, 2022, which can be used for repayment of principal and interest upon maturity[124]. - The group forecasts sufficient operating funds for the foreseeable future, supported by internal cash generation and undrawn bank financing[125]. - The company incurred interest expenses of HKD 684,000 on lease liabilities and HKD 13,310,000 on bank loans and other borrowings for the six months ended June 30, 2022[155]. Employee and Corporate Governance - Employee costs totaled HKD 43.3 million for the six months ended June 30, 2022, down from HKD 51.5 million in the same period of 2021[51]. - The company has complied with all applicable corporate governance code provisions during the reporting period[85]. - The company confirmed a net share-based payment expense of HKD 39,000 for the six months ended June 30, 2022, down from HKD 169,000 in the same period of 2021[83]. Assets and Liabilities - As of June 30, 2022, the net current liabilities amounted to HKD 87.0 million, an increase from HKD 54.5 million as of December 31, 2021[45]. - Total assets less current liabilities decreased to HKD 482,531 thousand from HKD 540,549 thousand, representing a decline of approximately 10.7%[104]. - Current assets decreased to HKD 512,183 thousand from HKD 610,857 thousand, reflecting a decrease of approximately 16.1%[102]. - Cash and cash equivalents decreased to HKD 39,520 thousand from HKD 59,671 thousand, a decline of approximately 33.8%[102]. - Trade receivables decreased to HKD 172,393 thousand from HKD 261,406 thousand, a reduction of about 34.1%[102]. - Non-current liabilities total decreased to HKD 128,516 thousand from HKD 138,991 thousand, a decline of approximately 7.5%[104]. - Equity attributable to owners of the parent decreased to HKD 354,015 thousand from HKD 401,558 thousand, a decrease of about 11.8%[104]. Stock Options and Shareholder Information - The company has a stock option plan effective for 10 years from June 12, 2015, aimed at incentivizing eligible participants[75]. - The exercise price for shares under the stock option plan cannot be lower than the higher of the closing price on the grant date or the average closing price over the previous five trading days[75]. - As of June 30, 2022, a total of 16,329,091 shares may be issued upon the exercise of all stock options granted under the stock option plan[76]. - During the mid-2022 period, a total of 1,004,334 stock options were exercised, 2,133,333 stock options expired, and 1,746,666 stock options were canceled[77]. - Mr. Chen Yuling holds 178,854,830 shares, representing 45.18% of the company's issued share capital[69]. - Ms. Wen Qihui owns 77,349,750 shares, accounting for 19.54% of the total issued shares[71]. - Fullgold Development, controlled by Mr. Chen, holds 81,929,000 shares, which is 20.69% of the issued share capital[71].

Financial Performance - PuraPharm Corporation Limited reported a significant increase in revenue, achieving a total of HKD 1.2 billion for the fiscal year, representing a growth of 15% compared to the previous year[1]. - The company reported a net profit margin of 12%, reflecting effective cost management and operational efficiencies achieved during the fiscal year[1]. - The company recorded a significant increase in sales of its concentrated traditional Chinese medicine granules, with a focus on the Hong Kong market[25]. - The company recorded a net loss of HKD 121.9 million in 2021, compared to a profit of HKD 31.7 million in 2020, primarily due to significant impairment of biological assets and goodwill in its Guizhou planting business[60]. - The company’s total revenue for the year ended December 31, 2021, was HKD 659.6 million, an increase of 9.6% compared to HKD 601.8 million in the previous year[114]. - The company confirmed an impairment loss of HKD 47.5 million related to biological assets for the year, compared to a fair value gain of HKD 20.8 million in the previous year[114]. - The group recorded a biological asset impairment loss of HKD 47.5 million, compared to a fair value gain of HKD 20.8 million in the previous year[158]. Market Expansion and Strategy - PuraPharm plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[1]. - The company is exploring potential acquisitions to enhance its product offerings, with a focus on companies that align with its strategic goals in the herbal medicine sector[1]. - Market expansion plans include entering EE new regions, which are anticipated to increase market share by FF%[23]. - The company is actively seeking local partners in the Greater Bay Area to develop reliable business plans and solutions[69]. - The company aims to expand its market presence through innovative product development and strategic partnerships with renowned universities[99]. Research and Development - The company is investing in new product development, with a budget allocation of HKD 100 million for R&D initiatives aimed at expanding its product line in herbal medicine[1]. - The company is investing in R&D for innovative technologies, allocating DD% of its budget towards this initiative to enhance product offerings[23]. - The company has established a new R&D center in Nanning in 2020 to enhance its product development capabilities and prepare for the standardization of concentrated Chinese medicine granules in China[49]. - The company has achieved significant results in the research of the rare medicinal herb, Ganoderma, with studies published in the renowned journal "Chinese Medicine Culture"[196]. Operational Efficiency - PuraPharm has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs by optimizing supply chain management[1]. - Operating expenses were managed effectively, resulting in a reduction of JJ% compared to the previous fiscal year[23]. - The company’s manufacturing processes are controlled by a central computer system, utilizing highly automated production equipment to enhance efficiency[82]. Environmental, Social, and Governance (ESG) Initiatives - PuraPharm's environmental, social, and governance (ESG) initiatives have been strengthened, with a commitment to reduce carbon emissions by 30% over the next five years[1]. - The company has increased its focus on environmental, social, and governance (ESG) issues due to the impacts of COVID-19, recognizing climate-related risks as a major threat to operations[182]. - The company has implemented a sustainable procurement policy to manage environmental and social impacts within its supply chain[198]. - The company prioritizes environmentally friendly and health-beneficial products during the product selection process[199]. Product Development and Innovation - The board of directors emphasized the importance of innovation, stating that 40% of revenue will come from new products launched in the last three years[1]. - New product launches are expected to contribute significantly to revenue, with an estimated impact of CC million in the upcoming quarter[23]. - The company launched the third-generation cloud-based "Traditional Chinese Medicine Assistant (TCMA 3.0)" system in July 2021, enhancing real-time database synchronization and patient information access for improved TCM services[53]. - The company expanded its product line by introducing a series of ten non-prescription concentrated Chinese medicine capsule products for overall health and wellness in 2020[50]. Financial Stability and Management - The company reported a strong balance sheet with total assets of II million, ensuring financial stability for future investments[23]. - The current ratio decreased from 1.0 as of December 31, 2020, to 0.9 as of December 31, 2021, mainly due to the reclassification of certain long-term loans to short-term financing[161]. - The debt-to-equity ratio increased from 0.9 as of December 31, 2020, to 1.2 as of December 31, 2021, primarily due to a decrease in equity from the net loss for the year[161]. Customer Engagement and Marketing - The company has established a network of traditional Chinese medicine clinics under the brand "Nongbenfang," providing modernized services and utilizing advanced management systems[103]. - A new marketing strategy has been implemented, aiming to increase brand awareness and customer engagement by HH%[23]. - The sales and marketing strategies are tailored to both retail and e-commerce channels to maximize reach and effectiveness[25].

Financial Performance - For the six months ended June 30, 2021, the company's revenue was HKD 302.8 million, an increase of HKD 22.3 million or 8.0% compared to the same period last year[8]. - The net profit for the same period was HKD 12.0 million, up from HKD 11.4 million in the previous year, driven by a rebound in sales of concentrated Chinese medicine granules and government subsidies[8]. - The group's revenue for the first half of 2021 was HKD 302.8 million, an increase of HKD 22.3 million or 8.0% compared to HKD 280.4 million in the same period last year[24]. - The net profit for the first half of 2021 was HKD 12.0 million, up from HKD 11.4 million in the same period last year, primarily due to a rebound in sales of concentrated Chinese medicine granules and government subsidies received[24]. - The gross profit margin for the first half of 2021 was 64.9%, an increase of 6.1% from 58.8% in the same period last year, attributed to a higher proportion of revenue from concentrated Chinese medicine granules[36]. - The company reported a profit of HKD 11,974,000 for the period, contributing to a total comprehensive income of HKD 12,813,000 for the six months ended June 30, 2021[105]. - The profit before tax increased to HKD 17,386,000, representing a growth of 6.1% compared to HKD 16,388,000 in the previous year[99]. - The company reported a decrease in the fair value of harvested biological assets to HKD 8,500,000 in 2021 from HKD 12,641,000 in 2020, a decline of approximately 32.5%[171]. Revenue Breakdown - Revenue from concentrated Chinese medicine granules in China was HKD 156.9 million, accounting for 51.8% of total revenue, a 29.1% increase from HKD 121.5 million in the previous year[18]. - Revenue from Hong Kong concentrated Chinese medicine granules was HKD 72.7 million, representing 24.0% of total revenue, a 6.4% increase from HKD 68.3 million in the previous year[19]. - Sales of concentrated Chinese medicine granules in China reached HKD 156.9 million, an increase of HKD 35.4 million or 29.1% compared to HKD 121.5 million in the same period last year[26]. - Direct sales of concentrated Chinese medicine granules in Hong Kong amounted to HKD 72.7 million, an increase of HKD 4.4 million or 6.4% from HKD 68.3 million in the same period last year[27]. - The revenue from the sale of concentrated Chinese medicine granules was HKD 247,311,000, up from HKD 207,885,000 in the previous year, indicating a growth of about 18.9%[131]. - The revenue from Chinese medicine health products decreased to HKD 39,358,000 from HKD 45,097,000, reflecting a decline of approximately 12.7%[131]. - The revenue from providing Chinese medicine outpatient services dropped significantly to HKD 9,925,000 from HKD 21,537,000, a decrease of about 53.8%[131]. Expenses and Costs - Sales and distribution expenses for the first half of 2021 were HKD 92.4 million, a decrease of HKD 4.4 million or 4.5% compared to HKD 96.8 million in the same period last year[39]. - The percentage of sales and distribution expenses to revenue decreased from 34.5% in the previous year to 30.5% in the first half of 2021[39]. - R&D costs increased by HKD 3.9 million or 48.3%, primarily due to an increase in the number of R&D personnel[41]. - General administrative expenses rose by HKD 3.4 million or 7.0%, mainly due to increased depreciation from a new production facility and higher director remuneration[41]. - Other expenses decreased to HKD 2.3 million, down HKD 4.2 million or 64.6% from HKD 6.5 million in the previous year, mainly due to reduced charitable donations[43]. - Financing costs increased by HKD 2.3 million or 20.8%, attributed to a rise in the average outstanding bank and other borrowings[44]. - The cost of goods sold was HKD 102,954,000, a decrease from HKD 109,412,000 in 2020, reflecting a reduction of 5.0%[139]. Assets and Liabilities - Total assets as of June 30, 2021, amounted to HKD 1,360,945,000, compared to HKD 1,374,577,000 as of December 31, 2020[101]. - Non-current assets increased to HKD 780,925,000 from HKD 766,899,000 at the end of 2020[101]. - Current assets decreased to HKD 580,020,000 from HKD 607,678,000 at the end of the previous year[101]. - The company's total equity amounted to HKD 526,995,000 as of June 30, 2021, compared to HKD 511,658,000 at the end of 2020, representing a growth of 3.0%[105]. - Non-current liabilities decreased to HKD 260,389,000 as of June 30, 2021, down from HKD 271,032,000 as of December 31, 2020, reflecting a decline of 3.9%[103]. - The company's interest-bearing bank and other borrowings stood at HKD 172,137,000 as of June 30, 2021, compared to HKD 178,992,000 as of December 31, 2020, a decrease of 3.0%[103]. - The total amount of bank loans and other borrowings with collateral was HKD 172,137,000 as of June 30, 2021[198]. Strategic Initiatives - The company expects continued strong growth in the Chinese economy in the second half of 2021, supported by favorable policies in the traditional Chinese medicine sector[10]. - The company plans to focus on the modernization of traditional Chinese medicine and the development of innovative health products featuring natural ingredients[10]. - The company aims to seek strategic partnerships to advance the modernization of traditional Chinese medicine, particularly in the Greater Bay Area[11]. - The company has allocated a budget to upgrade existing mobile applications, online stores, diagnostic software, and customer management systems[10]. Shareholder Information - As of June 30, 2021, Mr. Chen Yuling holds a 45.29% equity interest in the company, with additional holdings by other directors and executives, indicating significant insider ownership[67]. - PuraPharm Corp holds 77,349,750 shares, representing 19.59% of the company's issued share capital[73]. - Fullgold Development owns 81,929,000 shares, accounting for 20.75% of the company's issued share capital[73]. - The stock option plan allows for the issuance of up to 39,489,294 shares, equivalent to 10% of the issued shares as of the resolution date[76]. - The company recognized a net expense of HKD 169,000 for share incentives during the reporting period, compared to HKD 354,000 for the six months ending June 30, 2020[83]. Governance and Compliance - The company has complied with all applicable corporate governance code provisions during the reporting period, except for the separation of roles between the Chairman and CEO[85]. - The audit committee, established on June 12, 2015, consists of three independent non-executive directors and is responsible for overseeing financial reporting and internal controls[86].

Financial Performance - PuraPharm reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion in 2020[2] - The company achieved a net profit margin of 12%, translating to a net profit of HKD 144 million for the fiscal year[2] - The company recorded revenue of HKD 601.8 million in 2020, a decrease of HKD 94.1 million or 13.5% compared to 2019[58] - The company achieved a net profit of HKD 31.7 million in 2020, a significant improvement from a net loss of approximately HKD 227.3 million in 2019[58] - The group received significant non-recurring government subsidies amounting to HKD 65.8 million, an increase of HKD 53.7 million from HKD 12.1 million in the previous year[95] - The gross profit margin for the year ended December 31, 2020, was 61.5%, an increase of 4.2% from 57.3% the previous year[109] - Other income and gains increased to HKD 94.7 million, up HKD 77.2 million from HKD 17.5 million the previous year, primarily due to significant non-recurring government subsidies[111] Market Expansion and Product Development - PuraPharm plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share over the next three years[2] - The company is investing HKD 50 million in R&D for new product development, focusing on herbal supplements and traditional medicine[2] - PuraPharm aims to launch three new products in the next fiscal year, enhancing its product portfolio[2] - The company has identified potential acquisition targets in the health and wellness sector to further diversify its offerings[2] - The company is exploring potential mergers and acquisitions to facilitate market expansion and enhance its competitive edge[23] - The company is actively pursuing new product development and technological advancements to strengthen its market position[21] Research and Development - The company appointed Dr. Fan as the Executive Director and Chief R&D Officer, overseeing operations in China and Japan since November 2020[21] - Dr. Fan has over 20 years of experience in pharmaceutical research and development, previously serving as the head of pharmacological research at Kracie Pharmaceutical, Ltd[21] - The company is focused on expanding its R&D capabilities in both China and Japan, aiming to enhance product development and operational efficiency[21] - The company was selected by the National Administration of Traditional Chinese Medicine to conduct research on compound concentrated Chinese medicine granules, establishing a research base for the project[35] - The company has registered 5 patents and has 1 pending patent application during the reporting period[164] Sustainability and Environmental Initiatives - PuraPharm's commitment to sustainability includes plans to reduce packaging waste by 30% over the next two years[2] - The group is developing environmental goals and policies to manage climate-related risks, particularly concerning the supply of herbal raw materials[143] - The company aims to achieve carbon neutrality in alignment with China's and Hong Kong's carbon neutrality goals by developing its first climate change policy[167] - Total electricity consumption decreased to 10,099 MWh in 2020 from 10,890 MWh in 2019, representing a reduction of approximately 7.25%[169] - Total greenhouse gas emissions decreased to 12,208 tons of CO2 equivalent in 2020 from 13,652 tons in 2019, a reduction of approximately 10.61%[171] Operational Performance - The company’s operational performance improved in the second half of 2020 as the pandemic was successfully controlled in China starting in April[58] - In the second half of 2020, revenue increased by HKD 40.9 million or 14.6% compared to the first half, reaching HKD 321.4 million[97] - The adjusted operating loss (excluding government subsidies) improved by HKD 24.7 million or 84.0% from the first half to the second half of 2020[97] - The company has established a robust multi-layer supply chain system to enhance product promotion and distribution[61] Employee and Governance - The management team includes experienced professionals with extensive backgrounds in finance, law, and academia, enhancing the company's governance and strategic direction[23] - The group has no significant future investment or capital asset plans beyond those disclosed in the annual report[122] - The group emphasizes product quality assurance and compliance with environmental laws as the most critical social and environmental issues identified by stakeholders[147] - The company has established various communication channels for stakeholder engagement, including annual general meetings, investor presentations, and ESG surveys[145] Community Engagement and Social Responsibility - The company has committed to community investment policies aimed at promoting health in local and overseas communities[196] - The company has provided personal protective equipment and free annual health checks to frontline employees[189] - The company has donated traditional Chinese medicine prescriptions to hospitals and non-profit organizations to support frontline healthcare workers[200]

Financial Performance - For the six months ended June 30, 2020, the company's revenue was HKD 280.4 million, a decrease of HKD 53.1 million or 15.9% compared to HKD 333.6 million in the same period last year[32]. - The company recorded a net profit of HKD 11.4 million for the six months ended June 30, 2020, compared to a net loss of HKD 45.2 million in the same period last year, primarily due to significant non-recurring government subsidies received in China and Hong Kong[25]. - The total revenue for the first half of 2020 was HKD 280.4 million, a decrease of 15.9% compared to HKD 333.6 million in the same period of 2019[51]. - The net profit for the first half of 2020 was HKD 11.4 million, a significant improvement from a net loss of HKD 45.2 million in the same period of 2019, primarily due to increased non-recurring government subsidies[38]. - The company reported a loss before tax of HKD 16,388,000 for the six months ended June 30, 2020, compared to a profit of HKD 42,748,000 in the previous year[167]. - The net loss for the period was HKD 11,437,000, compared to a profit of HKD 45,180,000 in the same period last year[167]. - The company did not recommend any interim dividend for the six months ended June 30, 2020[159]. Revenue Breakdown - Sales of Chinese concentrated herbal granules in China decreased by HKD 12.5 million or 9.3%, from HKD 134.0 million in the previous year to HKD 121.5 million[38]. - Sales of concentrated herbal granules in Hong Kong fell by HKD 15.5 million or 18.5%, from HKD 83.9 million to HKD 68.3 million, impacted by the COVID-19 pandemic[39]. - The revenue from the herbal health products segment was HKD 45.1 million, down HKD 3.4 million or 7% from HKD 48.5 million in the previous year[45]. - The revenue from the farming segment increased by HKD 5.9 million or 38.5%, from HKD 15.6 million to HKD 21.5 million, driven by increased demand for agricultural products[49]. - The segment revenue breakdown includes HKD 121,498,000 from Chinese concentrated traditional Chinese medicine granules and HKD 68,311,000 from Hong Kong concentrated traditional Chinese medicine granules[199]. - The total external customer revenue from health products was HKD 45,097,000, contributing to the overall revenue growth[199]. Cost Management - The operating loss, excluding non-recurring government subsidies, was significantly lower than the same period last year due to stricter control over operating costs[25]. - Sales and distribution expenses decreased to HKD 96.8 million, down HKD 19.1 million or 16.5% from HKD 115.9 million in the previous year, attributed to reduced marketing activities due to COVID-19 and lower distribution costs related to decreased sales[55]. - The group’s administrative expenses totaled HKD 75.7 million, a reduction of HKD 30.0 million or 28.4% compared to HKD 105.7 million in the prior year, driven by cost control measures[57]. - Clinic operating expenses were HKD 18.7 million, down HKD 23.4 million or 55.6% from HKD 42.1 million in the previous year, mainly due to a reduction in the number of clinics from 57 to 26[57]. - Research and development costs decreased by HKD 3.8 million or 32.2%, primarily due to delays in development projects caused by COVID-19[57]. Strategic Initiatives - The company anticipates that the demand for high-quality health products will increase as consumer health awareness rises post-COVID-19, providing more opportunities for its Chinese medicine health product segment[26]. - The company plans to actively develop innovative health products to enrich its product portfolio and will focus on marketing these products through online platforms to revitalize the weak retail market[26]. - The company will closely monitor the business environment and actively adjust its business strategies to respond to challenges and seek opportunities[26]. - The company plans to enhance the performance of existing clinics and negotiate for reduced rent to achieve profitability[44]. - The company has plans to develop and launch two new patented traditional Chinese medicine products, with an estimated allocation of HKD 43.3 million for this purpose[114]. Financial Position - As of June 30, 2020, the group’s net current assets were HKD 43.7 million, compared to net current liabilities of HKD 41.4 million as of December 31, 2019[78]. - The group’s debt-to-equity ratio improved to 0.83 as of June 30, 2020, down from 1.3 as of December 31, 2019, due to a decrease in interest-bearing bank and other borrowings and the repayment of director loans[89]. - The total value of mortgaged assets as of June 30, 2020, was HKD 299.6 million, down from HKD 407.6 million as of December 31, 2019, indicating a decrease of approximately 26.6%[97]. - The company raised approximately HKD 105 million through a rights issue completed on March 2, 2020, with a net amount of approximately HKD 98.0 million after expenses[101]. - The company plans to utilize approximately 30% of the raised funds (HKD 86.5 million) for expanding production facilities and upgrading existing production lines[110]. - The company reported a net cash flow from operating activities of HKD 63,767,000 for the six months ended June 30, 2020, compared to HKD 56,628,000 in the same period of 2019, indicating a positive trend in operational efficiency[182]. Governance and Compliance - The company has complied with all applicable corporate governance code provisions during the six months ending June 30, 2020[150]. - The board has established an audit committee to provide independent opinions on the effectiveness of the group's financial reporting procedures and internal controls[152]. - The company has not engaged in any significant acquisitions, disposals, or major investments during the six months ended June 30, 2020[99]. Employee and Management - As of June 30, 2020, the company had a total of 707 employees, an increase from 696 employees as of December 31, 2019[91]. - Total employee costs (excluding directors' remuneration) for the six months ended June 30, 2020, were HKD 49.0 million, down from HKD 56.3 million for the same period in 2019, representing a decrease of approximately 23%[91]. - The company has no other significant interests or positions held by directors or senior management outside of those disclosed[143].